LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) Director David B. Roberts sold 5,025 shares of the business's stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $75.62, for a total transaction of $379,990.50. Following the completion of the sale, the director now directly owns 14,114 shares in the company, valued at $1,067,300.68. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
LeMaitre Vascular Trading Down 1.2 %
Shares of LeMaitre Vascular stock opened at $75.00 on Thursday. The company has a fifty day simple moving average of $66.55 and a 200-day simple moving average of $59.34. LeMaitre Vascular, Inc. has a 12-month low of $44.27 and a 12-month high of $76.24. The stock has a market cap of $1.68 billion, a price-to-earnings ratio of 49.67, a PEG ratio of 2.99 and a beta of 0.88.
LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share for the quarter, topping analysts' consensus estimates of $0.39 by $0.05. The firm had revenue of $53.48 million during the quarter, compared to analysts' expectations of $51.50 million. LeMaitre Vascular had a net margin of 16.99% and a return on equity of 11.57%. LeMaitre Vascular's quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.27 EPS. On average, analysts forecast that LeMaitre Vascular, Inc. will post 1.77 earnings per share for the current fiscal year.
LeMaitre Vascular Dividend Announcement
Elon to Transform U.S. Economy?
From Porter & Company | Ad
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites.
And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
One company holds a near-total monopoly on it.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 30th. Shareholders of record on Thursday, May 16th will be given a dividend of $0.16 per share. The ex-dividend date is Wednesday, May 15th. This represents a $0.64 dividend on an annualized basis and a yield of 0.85%. LeMaitre Vascular's payout ratio is currently 42.38%.
Hedge Funds Weigh In On LeMaitre Vascular
A number of large investors have recently made changes to their positions in LMAT. Mesirow Institutional Investment Management Inc. purchased a new position in shares of LeMaitre Vascular in the 4th quarter valued at about $8,837,000. Congress Asset Management Co. MA increased its holdings in shares of LeMaitre Vascular by 36.3% in the 3rd quarter. Congress Asset Management Co. MA now owns 508,379 shares of the medical instruments supplier's stock valued at $27,696,000 after purchasing an additional 135,266 shares in the last quarter. Ranger Investment Management L.P. increased its holdings in shares of LeMaitre Vascular by 15.8% in the 3rd quarter. Ranger Investment Management L.P. now owns 898,822 shares of the medical instruments supplier's stock valued at $48,968,000 after purchasing an additional 122,601 shares in the last quarter. Summit Creek Advisors LLC increased its holdings in shares of LeMaitre Vascular by 37.8% in the 4th quarter. Summit Creek Advisors LLC now owns 228,501 shares of the medical instruments supplier's stock valued at $12,970,000 after purchasing an additional 62,737 shares in the last quarter. Finally, Conestoga Capital Advisors LLC increased its holdings in shares of LeMaitre Vascular by 3.0% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,917,581 shares of the medical instruments supplier's stock valued at $104,470,000 after purchasing an additional 55,895 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on the stock. KeyCorp assumed coverage on shares of LeMaitre Vascular in a research note on Tuesday, February 6th. They issued a "sector weight" rating on the stock. Stifel Nicolaus raised shares of LeMaitre Vascular from a "hold" rating to a "buy" rating and boosted their price target for the company from $59.00 to $75.00 in a research note on Friday, April 26th. Barrington Research boosted their price target on shares of LeMaitre Vascular from $69.00 to $79.00 and gave the company an "outperform" rating in a research note on Friday, May 3rd. JMP Securities boosted their price target on shares of LeMaitre Vascular from $72.00 to $77.00 and gave the company a "market outperform" rating in a research note on Friday, May 3rd. Finally, StockNews.com raised shares of LeMaitre Vascular from a "hold" rating to a "buy" rating in a research note on Friday, May 3rd. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, LeMaitre Vascular has a consensus rating of "Moderate Buy" and an average target price of $73.83.
Get Our Latest Analysis on LMAT
About LeMaitre Vascular
(
Get Free Report)
LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
